Prosecution Insights
Last updated: April 19, 2026

Examiner: KWON, JOHN SEUNGJAI

Tech Center 1600 • Art Units: 1615

This examiner grants 45% of resolved cases

Performance Statistics

45.1%
Allow Rate
-14.9% vs TC avg
139
Total Applications
+19.7%
Interview Lift
1272
Avg Prosecution Days
Based on 102 resolved cases, 2023–2026

Rejection Statute Breakdown

1.8%
§101 Eligibility
11.3%
§102 Novelty
67.4%
§103 Obviousness
14.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18375162 ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF Non-Final OA Fennec Pharmaceuticals Inc.
17698906 COMPOSITIONS FOR DELIVERY OF DRUG COMBINATIONS TO TREAT LUNG DISEASE Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17815485 GRAPHENE BIOSCAFFOLDS AND THEIR USE IN CELLULAR THERAPY Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18508058 BIOMIMETIC LIPOSOMES AND METHODS OF MAKING AND USING THE SAME Non-Final OA Worcester Polytechnic Institute
17256944 SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS Non-Final OA Bayer Aktiengesellschaft
17339652 TREATMENT OF CYSTINOSIS Non-Final OA Nacuity Pharmaceuticals, Inc.
17156560 PRODRUG FOR THE TREATMENT OF DISEASE AND INJURY OF OXIDATIVE STRESS Non-Final OA Nacuity Pharmaceuticals, Inc.
17255799 SEED TREATMENT METHOD Final Rejection Bayer CropScience LP
18282554 FORMULATIONS COMPRISING A THERAPEUTIC PROTEIN AND AT LEAST ONE STABILIZER Non-Final OA UCB BIOPHARMA SRL
17955609 Implantable Medical Device for the Delivery of a Nucleic Acid Non-Final OA Celanese EVA Performance Polymers LLC
17705441 Implantable Medical Device for the Delivery of Nucleic Acid-Encapsulated Particles Non-Final OA Celanese EVA Performance Polymers LLC
18282380 VITAMIN D FORMULATIONS Non-Final OA SOLMIC BIOTECH GMBH
18208177 NOVEL DISINTEGRATION ORAL FILM FORMULATION WITH A CONTROLLED OR SUSTAINED ACTIVE RELEASE Final Rejection INTELGENX CORP.
17802078 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION Final Rejection HK INNO. N CORPORATION
18259552 WATER-SOLUBLE CANNABINOID FORMULATION AND PREPARATION METHOD THEREFOR Non-Final OA HANYI BIOTECHNOLOGY (BEIJING) CO., LTD
17926433 CANNABIDIOL AND ACTIVE DELIVERY SYSTEMS Final Rejection ELEMENTIS SPECIALTIES, INC.
18004601 ANTI-CANCER ACTIVITY OF PERBORATE SALTS Non-Final OA ALIYA PHARMACEUTICALS INC.
18011668 PLATELET MEMBRANE COATED NANOPARTICLES AND USES THEREOF Final Rejection CELLO THERAPEUTICS, INC.
17998524 SOLID ORAL COMPOSITIONS COMPRISING COMPOSITE MONOLITHIC MATRICES FOR CHRONOTROPIC ADMINISTRATION OF ACTIVE INGREDIENTS IN THE GASTROINTESTINAL TRACT Non-Final OA MOGON PHARMACEUTICALS SAGL
17910239 A NANOPARTICLE FOR USE IN THE TREATMENT OF AN OCULAR DISEASE Non-Final OA UNIVERSITÄT REGENSBURG
17697779 IMMEDIATE POST-PROCEDURE RECOVERY FORMULATION AND METHOD Non-Final OA JAMRM, LLC
17620167 BIODEGRADABLE DRUG-ELUTING EMBOLIC PARTICLES FOR DELIVERY OF THERAPEUTIC AGENTS Non-Final OA Jeffrey WANG
17347148 HYDROGEL COMPOSITIONS ENCAPSULATING SOLID PARTICLES Non-Final OA GALDERMA HOLDING SA
17284650 SUSPENSION FORMULATIONS OF HIGH LOAD DISPERSIONS Final Rejection Austin Research Labs Corp.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month